Your browser doesn't support javascript.
loading
Long-term Survival Outcomes of 'Low Risk' Ductal Carcinoma in situ from a Territory-wide Cancer Registry.
Co, M; Ngan, R K C; Mang, O W K; Tam, A H P; Wong, K H; Kwong, A.
Afiliación
  • Co M; Division of Breast Surgery, Department of Surgery, The University of Hong Kong, Hong Kong; Department of Surgery, Queen Mary Hospital, Hong Kong.
  • Ngan RKC; Department of Clinical Oncology, The University of Hong Kong, Hong Kong; Hong Kong Cancer Registry, Hospital Authority, Hong Kong; Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong.
  • Mang OWK; Hong Kong Cancer Registry, Hospital Authority, Hong Kong.
  • Tam AHP; Hong Kong Cancer Registry, Hospital Authority, Hong Kong.
  • Wong KH; Hong Kong Cancer Registry, Hospital Authority, Hong Kong; Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong.
  • Kwong A; Division of Breast Surgery, Department of Surgery, The University of Hong Kong, Hong Kong; Department of Surgery, Queen Mary Hospital, Hong Kong. Electronic address: avakwong@hku.hk.
Clin Oncol (R Coll Radiol) ; 33(1): 40-45, 2021 01.
Article en En | MEDLINE | ID: mdl-32713775
AIMS: The LORIS trial is an ongoing phase III clinical trial on low risk ductal carcinoma in situ (DCIS). DCIS patients aged ≥46 years with screen-detected low/intermediate nuclear grade were considered low risk and were randomised into surveillance or standard surgery. Here we review the 10-year territory-wide breast cancer registry database and evaluate the clinical outcomes of low versus high risk DCIS patients. MATERIALS AND METHODS: This was a retrospective study of a prospectively maintained territory-wide breast cancer registry in Hong Kong. RESULTS: Between 1997 and 2006, 1391 DCIS patients were identified from the Hong Kong cancer registry breast cancer database. The mean age at diagnosis was 49.2 years (range 30-70). In total, 372 patients were classified as 'low risk', whereas the remaining 777 patients were classified as 'high risk'. After a median follow-up of 11.6 years, the 10-year overall breast cancer-specific survival of the entire DCIS cohort was 1136/1149 (98.9%). Overall breast cancer-specific survival of low risk DCIS was 99.5%, whereas that in high risk DCIS was 98.6% (Log-rank test, P = 0.208). Forty-six (12.4%) patients in the LORIS low risk group did not receive surgery, whereas 93 (12%) patients in the LORIS high risk group did not receive surgery. The 10-year breast cancer-specific survival in the non-operated low risk DCIS group was 97.8%; that in the non-operated high risk DCIS group was 96.7% (P = 1). CONCLUSION: Long-term survival of DCIS was excellent, especially in low risk DCIS, regardless of surgical treatment.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Carcinoma Intraductal no Infiltrante / Ajuste de Riesgo / Espera Vigilante Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Middle aged País/Región como asunto: Asia Idioma: En Revista: Clin Oncol (R Coll Radiol) Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Hong Kong Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Carcinoma Intraductal no Infiltrante / Ajuste de Riesgo / Espera Vigilante Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Middle aged País/Región como asunto: Asia Idioma: En Revista: Clin Oncol (R Coll Radiol) Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Hong Kong Pais de publicación: Reino Unido